Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Three versus five years of adjuvant imatinib in high‑risk operable GIST
2024-512243-23-00Phase 3Authorised
- Sponsor
- Region Skåne
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised trial in gastrointestinal stromal tumor (GIST) comparing Extended adjuvant imatinib (5-year total) with Observation after 3 years of adjuvant imatinib (2 arms). Primary endpoint: Recurrence-free survival. Planned start Oct 2024; status: authorised.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2024-512243-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512243-23-00.